These data highlight the dual potential of ClpP modulators to induce mitochondrial stress and sensitize tumors to existing therapies, particularly in aggressive subtypes like TNBC and HER2-positive breast cancer (Figure 12). The gene discussed is ERBB2; the disease is breast carcinoma.